title: Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin.
abstract: The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the subcutaneous formulation of immunoglobulin, which has been used in some patients with other autoimmune diseases. We report a case of SLE refractory to classical therapies. High-dose intravenous immunoglobulin was effective, but gave rise to significant side effects. The patient was successfully treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and laboratory remission. A lower immunoglobulin dose was needed and no side effects were observed, compared to the intravenous administration. Subcutaneous immunoglobulin could be a better-tolerated and cost-saving therapeutic option for select SLE patients.
authors: Department of Dermatology, Hospital S. António dos Capuchos, Centro Hospitalar Lisboa Central, Portugal afmbrasileiro@gmail.com.
authors: A
authors: A
authors: Brasileiro
authors: Department of Internal Medicine, Hospital S. António dos Capuchos, Centro Hospitalar Lisboa Central, Portugal.
authors: J
authors: J
authors: Fonseca Oliveira
authors: Department of Internal Medicine, Hospital S. António dos Capuchos, Centro Hospitalar Lisboa Central, Portugal.
authors: S
authors: S
authors: Pinheiro
authors: Department of Dermatology, Hospital S. António dos Capuchos, Centro Hospitalar Lisboa Central, Portugal.
authors: M J
authors: MJ
authors: Paiva-Lopes
mesh_terms: D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors
keywords: Systemic lupus erythematosus; cutaneous lupus; discoid lupus